English
BCL-2 TR-FRET Assay Kit -384 reactions
BCL-2 TR-FRET Assay Kit -384 reactions
Artikelnummer
BPS50222-2
Verpackungseinheit
384 reactions
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen small molecule inhibitors in drug discovery and high-throughput screening (HTS) applications.
Background: B-cell lymphoma 2 (BCL-2) is a member of the BCL family that regulates apoptosis through pro-apoptotic or anti-apoptotic signals. BCL-2 is normally localized at the outer membrane of mitochondria and blocks pro-apoptotic signals, promoting cell survival. Genetic alteration of BCL-2 has been observed in various types of cancer, including lymphoma, leukemia, melanoma, as well as breast and prostate cancer. The protein is also involved in cancer cell resistance to treatment due to its pro-survival functions. ABT-199, also known as Venetoclax, is a BH3-mimetic that specifically blocks the function of BCL-2 and was the first BCL-2 targeted agent to receive FDA approval (in 2016). It is now approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma
Description: The BCL-2 TR-FRET Assay Kit is designed to measure the inhibition of BCL-2 (B-cell lymphoma 2) binding to its ligand in a homogeneous 96 or 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. This kit contains enough recombinant BCL-2, BCL-2 peptide ligand, assay buffer, Anti-His Terbium-Labeled Donor, and Dye-labeled Streptavidin Acceptor for 96 or 384 reactions
Figure 1. Illustration of the BCL-2 TR-FRET Assay Kit principle.
A sample containing terbium-labeled donor, dye-labeled acceptor, BCL-2, peptide ligand, and an inhibitor is incubated for 180 minutes. The Donor Terbium-labeled anti-His antibody binds to His-tagged BCL-2. The BCL-2 peptide ligand is labeled with biotin, which allows the dye-labeled streptavidin acceptor to bind to the BCL-2 peptide ligand. The TR-FRET signal is generated by proximity induced upon interaction of BCL-2 with the BCL-2 peptide ligand. Then, the fluorescence intensity is measured using a fluorescence reader capable of TR-FRET measurements. The signal generated is proportional to BCL-2 activity.
Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
Uniprot: P10415
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: Filippakopoulos, P., et al.,Cell 2012; 149:214.
Applications: Screen small molecule inhibitors in drug discovery and high-throughput screening (HTS) applications.
Background: B-cell lymphoma 2 (BCL-2) is a member of the BCL family that regulates apoptosis through pro-apoptotic or anti-apoptotic signals. BCL-2 is normally localized at the outer membrane of mitochondria and blocks pro-apoptotic signals, promoting cell survival. Genetic alteration of BCL-2 has been observed in various types of cancer, including lymphoma, leukemia, melanoma, as well as breast and prostate cancer. The protein is also involved in cancer cell resistance to treatment due to its pro-survival functions. ABT-199, also known as Venetoclax, is a BH3-mimetic that specifically blocks the function of BCL-2 and was the first BCL-2 targeted agent to receive FDA approval (in 2016). It is now approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma
Description: The BCL-2 TR-FRET Assay Kit is designed to measure the inhibition of BCL-2 (B-cell lymphoma 2) binding to its ligand in a homogeneous 96 or 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. This kit contains enough recombinant BCL-2, BCL-2 peptide ligand, assay buffer, Anti-His Terbium-Labeled Donor, and Dye-labeled Streptavidin Acceptor for 96 or 384 reactions
Figure 1. Illustration of the BCL-2 TR-FRET Assay Kit principle.A sample containing terbium-labeled donor, dye-labeled acceptor, BCL-2, peptide ligand, and an inhibitor is incubated for 180 minutes. The Donor Terbium-labeled anti-His antibody binds to His-tagged BCL-2. The BCL-2 peptide ligand is labeled with biotin, which allows the dye-labeled streptavidin acceptor to bind to the BCL-2 peptide ligand. The TR-FRET signal is generated by proximity induced upon interaction of BCL-2 with the BCL-2 peptide ligand. Then, the fluorescence intensity is measured using a fluorescence reader capable of TR-FRET measurements. The signal generated is proportional to BCL-2 activity.
Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
Uniprot: P10415
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: Filippakopoulos, P., et al.,Cell 2012; 149:214.
| Artikelnummer | BPS50222-2 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 50222-2 |
| Verpackungseinheit | 384 reactions |
| Mengeneinheit | PAK |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
